RECURRENT MALIGNANT SOLID NEOPLASM

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This early-phase study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma that hasn't responded to standard treatments will take part. The goal is to find side effects and the …

This study tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread will receive the combination. The goal is to find the best dose and see if the treat…

This study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.

This study tests an experimental drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by …

This study tests a new drug combination (DT2216 plus irinotecan) in children, teens, and young adults whose solid tumors have returned or not responded to treatment. The goal is to find the safest dose and see if the combo can shrink tumors, especially in a rare liver cancer call…

This early-phase trial tests the drug talazoparib combined with one of three other drugs (palbociclib, axitinib, or crizotinib) in people with advanced or metastatic solid tumors. The goal is to find the safest dose and see if the combinations help control tumor growth. About 111…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …

This study compares two drugs, neratinib and palbociclib, used together versus neratinib alone for people with HER2-positive gynecologic and other solid tumors (excluding breast cancer). The goal is to see if the combination can shrink or slow cancer growth. About 70 adults with …

This study tests a parenting support program for parents with advanced cancer and their spouses. The program aims to reduce parenting worries, improve family communication about cancer, and boost emotional well-being. About 120 families with children ages 4 to 16 will take part.

This study aims to understand why some people who have had ovarian or other solid cancers later develop blood cancers. Researchers will follow 2,000 participants to identify genetic and environmental risk factors. The goal is to improve monitoring and prevention for cancer surviv…

This study screens patients with advanced solid tumors to find genetic changes in their cancer cells. Based on those results, patients may be matched to a treatment trial that targets their specific tumor mutations. The goal is to improve how doctors choose combination therapies …

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…

This study collects tissue and blood samples from 5,000 cancer patients to create lab models, like patient-derived xenografts and cell lines. The goal is to help scientists better understand cancer and test new treatments. Participants must be over 2 months old and have a confirm…